Oncolytic Virus Therapy Market Report 2026

Oncolytic Virus Therapy Market Overview

• Oncolytic Virus Therapy market size has reached to $0.23 billion in 2025 • Expected to grow to $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 23.7% • Growth Driver: Rising Cancer Prevalence Drives Growth In The Oncolytic Virus Therapy Market • Market Trend: Accelerating Oncolytic Virus Therapy Development Through Regulatory Approvals • North America was the largest region and fastest growing region.

What Is Covered Under Oncolytic Virus Therapy Market?

Oncolytic virus therapy, also known as virotherapy, is a type of cancer treatment that utilizes viruses to target and destroy cancer cells in the body. The main objective of oncolytic virus therapy is to use viruses that have been genetically modified or naturally occur in a way that allows them to selectively infect and replicate within cancer cells while sparing healthy cells. The main types of oncolytic virus therapy are HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), and others. HSV-based oncolytic virus therapy utilizes the herpes simplex virus (HSV) as the platform for treatment. The various virus types include genetically engineered oncolytic viruses and oncolytic wild-type viruses. These are used in various applications such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumor, and blood cancer and are also used by end-users such as hospitals, specialty clinics, and cancer research institutes.

What Is The Oncolytic Virus Therapy Market Growth Forecast?

The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 23.7%. The growth in the forecast period can be attributed to rising demand for genetically engineered oncolytic viruses, increasing adoption in lung, prostate, and brain cancers, growth of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, expansion of clinical trial infrastructure in emerging markets. Major trends in the forecast period include rising adoption of ai and big data in oncolytic virus research, increasing use of genomics and precision medicine for therapy design, growing implementation of digital platforms for clinical trial monitoring, rising automation in virus production and quality assurance, increasing iot-based monitoring of virus storage and distribution.

Global Oncolytic Virus Therapy Market Segmentation

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types 2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses 3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer 4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes Subsegments: 1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches 2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies 3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches 4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies 5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments 6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Is The Driver Of The Oncolytic Virus Therapy Market?

The increasing prevalence of cancer cases is expected to propel the growth of the oncolytic virus therapy market going forward. Cancer is a term used to describe a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Oncolytic virus therapy offers the potential to selectively target and destroy cancer cells while stimulating an immune response against the tumor, providing a dual mechanism of action for effective cancer treatment. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer cases is driving the growth of the oncolytic virus therapy industry.

Key Players In The Global Oncolytic Virus Therapy Market

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Global Oncolytic Virus Therapy Market Trends and Insights

Major companies operating in the oncolytic virus therapy market are concentrating on obtaining regulatory approvals to expedite the introduction of innovative therapies for cancer treatment. Regulatory approvals refer to the process by which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for use in the market. For instance, in March 2024, ImmVira, a China-based biotechnology company, received Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT, aimed at treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.

What Are Latest Mergers And Acquisitions In The Oncolytic Virus Therapy Market?

In February 2025, UroGen Pharma Ltd., a US-Israel-based biotechnology company, acquired assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc., for an undisclosed amount. Through this acquisition, UroGen aims to expand its oncolytic virus therapy pipeline and strengthen its technological capabilities in immunotherapy, particularly for bladder cancer and other locally treated malignancies. IconOVir Bio is a US-based developer of next-generation oncolytic viruses, including ICVB 1042, designed to selectively kill cancer cells and trigger immune responses.

Regional Outlook

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oncolytic Virus Therapy Market?

The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oncolytic Virus Therapy Market Report 2026?

The oncolytic virus therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.